FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bure	den								
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROBINS HARLAN S						2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]									k all applic	cable) or	g Person(s) to Issi 10% Ow Other (s		vner specify
	ast) (First) (Middle) /O ADAPTIVE BIOTECHNOLOGIES CORP. UITE 200					3. Date of Earliest Transaction (Month/Day/Year) 04/20/2021											below)		
(Street) SEATTL	Street) SEATTLE WA 98102				_ ^{4.} _	4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																
1. Title of	Security (Ins		ole I - No	2. Trans		2	2A. Dee	med	3.		4. Securitie	es Acquir	ed (A) o	r	5. Amou	nt of	6. Owner	ship	7. Nature
					Date (Month/Day/Year		(ear) Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. 8)		Disposed (Of (D) (Ins	tr. 3, 4 a	ına 5)	Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	lirect 4)	of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	е	Transac (Instr. 3	tion(s)			(111511.4)
Common	Stock			04/20/2021		1			M ⁽¹⁾		11,685	85 A :		5.32	81,045		D		
Common Stock				04/20/2021		1			S ⁽¹⁾		8,685 D		\$40).24 ⁽²⁾	72,360		D		
Common Stock				04/20/2021		1			S ⁽¹⁾		3,000 Г		\$41	.35(3)	69,360		D		
Common Stock				04/21/2021		1			M ⁽¹⁾		7,790	A	\$(\$6.32		77,150		D	
Common Stock				04/2	04/21/2021				S ⁽¹⁾		500	D	\$39	\$39.85(4)		76,650		D	
Common Stock 04/21				1/202	1			S ⁽¹⁾		2,090	D	\$41	11.17 ⁽⁵⁾ 74		,560	D			
Common Stock 04/21/2					1/202	2021		S ⁽¹⁾		5,200	D	\$41	.79(6)	69,360		D			
Common Stock 04/22/2					2/202	2021			M ⁽¹⁾		7,790	A	\$(_		,150	D	D	
Common Stock 04/22/2					2/202				S ⁽¹⁾		4,280			2.85(7)	1		D		
Common Stock 04/22/2								S ⁽¹⁾				<u> </u>	8.59 ⁽⁸⁾			D			
		•	Table II -								osed of, convertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transactic Code (Insi		on of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		[8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e Ow s For ally Dire or I	nership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock					Code	code V			Date Exercisa	able	Expiration Date	Title	Amo or Num of Shar	ber					

Explanation of Responses:

\$6.32

\$6.32

\$6.32

04/20/2021

04/21/2021

04/22/2021

Option (Right to

(Right to

Buy) Stock

Option

Buy)

(Right to

Buy) Stock Option

1. These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

M⁽¹⁾

M⁽¹⁾

M⁽¹⁾

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$39.90 to 40.77, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the $number\ of\ shares\ sold\ at\ each\ separate\ price\ within\ the\ ranges\ set\ forth\ in\ any\ footnotes\ to\ this\ Form\ 4.$

11,685

7,790

7,790

(9)

(9)

(9)

Common Stock

Commo

Stock

Stock

11,685

7,790

7,790

\$0.00

\$0.00

\$0.00

155,800

148,010

140,220

D

D

D

06/09/2025

06/09/2025

06/09/2025

- 3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$40.90 to 41.69, inclusive.
- 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$39.40 to 40.39, inclusive.
- 5. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$40.44 to 41.43, inclusive.
- 6. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$41.48 to 42.17, inclusive.
- 7. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$42.37 to 43.34, inclusive.
- 8. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$43.38 to 43.85, inclusive.
- 9. The option is fully vested and exercisable.

Remarks:

/s/ Harlan Robins by Eric Billings, Attorney-in-Fact

** Signature of Reporting Person Date

04/22/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.